RFA
IBB icon

Rollins Financial Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Rollins Financial Advisors’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,637
Closed -$276K – 173
2026
Q1 		$276K Sell
1,637
-286
-15% -$48.9K 0.04% 142
2025
Q4 		$325K Buy
+1,923
New +$312K 0.05% 121

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.9% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Rollins Financial Advisors's IBB Position: Q2 2026 in Review

Rollins Financial Advisors sold out of iShares Biotechnology ETF (IBB) in Q2 2026, closing a stake of 1,637 shares — an estimated $276K sold.

Rollins Financial Advisors first reported a position in IBB in Q4 2025 and held it in 2 quarters. The position peaked at $325K in Q4 2025. 960 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Rollins Financial Advisors reported no remaining iShares Biotechnology ETF position as of Q2 2026 after selling out during the quarter.
  • Rollins Financial Advisors sold 1,637 iShares Biotechnology ETF shares in Q2 2026, an estimated $276K.
  • Rollins Financial Advisors first reported a position in iShares Biotechnology ETF in Q4 2025 and held it in 2 quarters.
  • Rollins Financial Advisors's iShares Biotechnology ETF position peaked at $325K in Q4 2025.
  • 960 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Rollins Financial Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.